B7家族与肿瘤化疗耐药

B7 family and chemotherapy resistance in tumors

肿瘤化疗的多药耐药性(multi-drug resistance,MDR)是提高抗肿瘤治疗效果的主要挑战之一。如何克服肿瘤MDR的问题,已成为当前肿瘤治疗领域的重要研究方向。随着对肿瘤免疫微环境的深入理解,肿瘤免疫逃逸机制以及免疫治疗已经成为肿瘤免疫学研究的热点之一。由于较高的安全性、疗效的长效性以及广泛的适用性,免疫疗法在恶性肿瘤的治疗中引起了越来越多的关注。其中,靶向B7家族辅助治疗已经被应用于多种实体瘤的临床治疗。B7家族属于免疫球蛋白超家族,它们在肿瘤微环境内的肿瘤细胞和免疫细胞中表达,与肿瘤细胞的增殖和转移密切相关。B7家族分子在肿瘤耐药性的发展中起到了重要作用,因此,通过靶向B7家族分子进行的免疫疗法可能具有克服恶性肿瘤MDR的潜力,从而实现治疗效果的提升。本文就B7家族分子与肿瘤MDR的最新研究进展进行综述,为克服肿瘤MDR和肿瘤治疗提供有前景的方法。

Multi-drug resistance(MDR)in cancer chemotherapy is a major challenge in improving the efficacy of anti-tumor treatments.Overcoming the problem of tumor MDR has become an important research area in current tumor therapy.With an increasing understanding of the tumor immune microenvironment,tumor immune escape mechanisms as well as immunotherapy have become one of the hotspots in tumor immunology research.Immunotherapy has received increasing attention in the treatment of malignancies due to its high safety profile,durable efficacy,and broad applicability.In particular,targeting the B7 family in the adjuvant treatment of malignant tumors has been used in the clinical management of a wide range of solid tumors.The B7 family,a member of the immunoglobulin superfamily,is expressed in both tumor and immune cells within the tumor microenvironment and is intimately involved in tumor cell proliferation and metastasis.Recent research has highlighted the pivotal role of B7 family molecules in the development of tumor resistance,suggesting that immunotherapeutic interventions targeting B7 family molecules hold promise for overcoming MDR in malignant tumors,thereby improving treatment outcomes.This review summarizes the latest advances in the study of B7 family molecules and tumor MDR,offering prospective approaches for overcoming tumor MDR and tumor therapy.